PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsHydrocortisone butyrate
Hydrocortisone butyrate
Alkindi, Efmody, Hydrocortisone Butyrate, Locoid, Plenadren (hydrocortisone butyrate) is a small molecule pharmaceutical. Hydrocortisone butyrate was first approved as Locoid on 1982-03-31. It is used to treat adrenal insufficiency, congenital adrenal hyperplasia, contact dermatitis, facial dermatoses, and foot dermatoses amongst others in the USA. It has been approved in Europe to treat adrenal insufficiency and congenital adrenal hyperplasia.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
digestive system diseasesD004066
respiratory tract diseasesD012140
urogenital diseasesD000091642
cardiovascular diseasesD002318
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
immune system diseasesD007154
Show 1 more
Trade Name
FDA
EMA
Hydrocortisone butyrate, Locoid (discontinued: Hydrocortisone butyrate, Locoid)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Hydrocortisone butyrate
Tradename
Company
Number
Date
Products
LOCOIDBausch Health CompaniesN-018514 RX1982-03-31
1 products, RLD, RS
LOCOIDBausch Health CompaniesN-019116 RX1987-02-25
1 products, RLD, RS
LOCOID LIPOCREAMPrecision DermatologyN-020769 RX1997-09-08
1 products, RLD, RS
LOCOIDPrecision DermatologyN-018652 RX1982-10-29
1 products, RLD, RS
Show 4 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
aquax-hunapproved drug other2024-12-31
evesseANDA2026-02-28
hydrocortisone butyrateANDA2026-07-14
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Hydrocortisone Butyrate, Locoid, Bausch
79818772025-01-23DP
ATC Codes
D: Dermatologicals
— D07: Corticosteroids, dermatological preparations
— D07A: Corticosteroid dermatological preparations, plain
— D07AB: Corticosteroids, moderately potent (group ii)
— D07AB02: Hydrocortisone butyrate
— D07B: Corticosteroids, combinations with antiseptics
— D07BB: Corticosteroids, moderately potent, combinations with antiseptics
— D07BB04: Hydrocortisone butyrate and antiseptics
HCPCS
No data
Clinical
Clinical Trials
1568 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Precursor cell lymphoblastic leukemia-lymphomaD054198—C91.02844183481
Adrenal insufficiencyD000309——6611223679
Anxiety disordersD001008EFO_0006788F41.176—35367
LeukemiaD007938—C952030142460
DepressionD003863—F33.975224860
Septic shockD012772—A48.311218111855
Healthy volunteers/patients———124182448
Cushing syndromeD003480EFO_0003099E24211513048
SepsisD018805EFO_0001420A41.9181491746
Psychological stressD013315——2—114044
Show 164 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Prostatic neoplasmsD011471—C615137—629
Myeloid leukemia acuteD015470—C92.016113——27
Physiological stressD013312————1—2223
Breast neoplasmsD001943EFO_0003869C50—43—1520
Covid-19D000086382—U07.1——7—1219
Non-hodgkin lymphomaD008228—C85.96112—219
Burkitt lymphomaD002051—C83.71115——16
NeoplasmsD009369—C80381—616
Psychological well-beingD000092862——1—1—1416
AlcoholismD000437EFO_0003829F10.1511—915
Show 115 more
Indications Phases 2
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Substance-related disordersD019966EFO_0003890F131———89
OverweightD050177—E66.31———78
Caregiver burdenD000084802——1———56
Blood pressureD001794EFO_0004325—2———35
Chronic painD059350——1———45
Cocaine-related disordersD019970—F141———45
Sleep deprivationD012892—F51.122———24
FibromyalgiaD005356EFO_0005687M79.11———34
AgnosiaD000377EFO_0007136F881———34
Alcohol drinkingD000428EFO_0004329—1———34
Show 66 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Dental implantsD015921——————1111
Dental anxietyD016854——————1010
Psychological burnoutD000077062—Z73.0————99
Breast feedingD001942——————88
Psychological distressD000079225——————88
Nursing careD009732——————77
Occupational stressD000073397——————77
PregnancyD011247EFO_0002950Z33.1————77
ExerciseD015444EFO_0000483—————66
InfertilityD007246EFO_0000545—————55
Show 377 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameHydrocortisone butyrate
INNhydrocortisone
Description
Cortisol 17-butyrate is cortisol esterified with butyric acid at the 17-hydroxy group. It has a role as a dermatologic drug and a drug allergen. It is a cortisol ester, a butyrate ester and a primary alpha-hydroxy ketone.
Classification
Small molecule
Drug classcortisone derivatives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Identifiers
PDB—
CAS-ID13609-67-1
RxCUI—
ChEMBL IDCHEMBL1683
ChEBI ID31674
PubChem CID—
DrugBankDB00741
UNII IDWI4X0X7BPJ (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 410 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2,063 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use